CX Institutional grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 508 shares of the medical research company’s stock after acquiring an additional 26 shares during the period. CX Institutional’s holdings in Thermo Fisher Scientific were worth $237,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Charles Schwab Investment Management Inc. raised its stake in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,915,477 shares of the medical research company’s stock worth $845,722,000 after acquiring an additional 48,950 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Thermo Fisher Scientific by 1.8% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 121,276 shares of the medical research company’s stock valued at $53,546,000 after acquiring an additional 2,100 shares in the last quarter. TPI Fund Managers Ltd raised its holdings in Thermo Fisher Scientific by 0.7% during the third quarter. TPI Fund Managers Ltd now owns 43,879 shares of the medical research company’s stock worth $19,373,000 after purchasing an additional 316 shares in the last quarter. Bainco International Investors raised its holdings in Thermo Fisher Scientific by 1.7% during the fourth quarter. Bainco International Investors now owns 23,718 shares of the medical research company’s stock worth $11,048,000 after purchasing an additional 391 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 218.3% in the 3rd quarter. Cerity Partners LLC now owns 70,308 shares of the medical research company’s stock valued at $31,043,000 after acquiring an additional 48,217 shares during the period. Institutional investors and hedge funds own 88.12% of the company’s stock.
Several research analysts have recently issued reports on the company. Atlantic Securities initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 30th. They set an “overweight” rating and a $494.00 price target for the company. Needham & Company LLC upped their price target on Thermo Fisher Scientific from $477.00 to $539.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Smith Barney Citigroup cut Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 16th. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $460.00 to $480.00 and gave the company an “overweight” rating in a research report on Monday, October 5th. Finally, SVB Leerink upped their price target on Thermo Fisher Scientific from $470.00 to $525.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $492.58.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $5.63 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $1.26. The firm had revenue of $8.25 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The business’s revenue for the quarter was up 31.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.94 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 15.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be issued a $0.22 dividend. The ex-dividend date is Monday, December 14th. This represents a $0.88 annualized dividend and a dividend yield of 0.18%. Thermo Fisher Scientific’s payout ratio is currently 7.13%.
Thermo Fisher Scientific declared that its board has approved a share buyback plan on Thursday, November 5th that permits the company to repurchase $2.50 billion in shares. This repurchase authorization permits the medical research company to buy up to 1.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $479.94, for a total value of $4,799,400.00. Following the completion of the sale, the chief executive officer now owns 228,694 shares in the company, valued at approximately $109,759,398.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Mark Stevenson sold 14,113 shares of the stock in a transaction that occurred on Friday, December 4th. The stock was sold at an average price of $476.46, for a total value of $6,724,279.98. Following the completion of the sale, the chief operating officer now owns 58,005 shares of the company’s stock, valued at approximately $27,637,062.30. The disclosure for this sale can be found here. Insiders have sold a total of 38,246 shares of company stock worth $18,220,461 over the last quarter. Corporate insiders own 0.44% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.